Clinical Journal of Gastroenterology

, Volume 6, Issue 2, pp 160–163

Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient

  • Tatsuo Kanda
  • Shingo Nakamoto
  • Makoto Arai
  • Tatsuo Miyamura
  • Shuang Wu
  • Keiichi Fujiwara
  • Osamu Yokosuka
Case Report

Abstract

We describe a patient infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon with or without ribavirin seven times but who then achieved sustained virological response by the combination of interferon-beta plus ribavirin treatment for 48 weeks. He did not respond to stronger treatment such as prolonged peginterferon plus ribavirin treatment for 87 weeks. It might be rare to treat a patient with interferon 8 times considering the cost and time, since patients failing interferon treatment several times are regarded to be refractory to interferon. It is possible that the difference in biological effects between interferon-alfa and interferon-beta might have resulted in a different outcome in our patient. Interferon-beta plus ribavirin therapy might be one of the treatment options for certain patients chronically infected with HCV who do not respond to standard care treatment.

Keywords

Hepatitis C HCV genotype 1 Interferon-beta Neutralizing antibody Ribavirin Sustained virological response 

References

  1. 1.
    Asahina Y, Izumi N, Oketani M, Kumada H, Koike K, Suzuki F, et al. Treatment guidelines of hepatitis C. The committee for hepatitis clinical guidelines, Japan Society of Hepatology (in Japanese with English abstract). Kanzo. 2012;53:355–95.Google Scholar
  2. 2.
    Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infected. Hepatol Int. 2012;6:409–35.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRefGoogle Scholar
  4. 4.
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol. 2004;10:12–6.PubMedGoogle Scholar
  8. 8.
    Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Oohashi S, Nishiura S. Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin. Hepatol Res. 2012;42:241–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, et al. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Intern Med. 2010;49:957–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, et al. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol. 2011;46:955–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, et al. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol. 2012;84:1199–207.PubMedCrossRefGoogle Scholar
  12. 12.
    Okushin H, Morii K, Yuasa S. Efficacy of the combination therapy using twice-a-day IFN-beta for chronic hepatitis C (in Japanese with English abstract). Kanzo. 1995;49:735.Google Scholar
  13. 13.
    Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, et al. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver Int. 2006;26:520–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Miyauchi T, Kanda T, Imazeki F, Mikata R, Tawada A, Arai M, et al. Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatol Int. 2012. doi:10.1007/s12072-012-9349-4.
  15. 15.
    Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, et al. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol. 2011;46:944–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, et al. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern Med. 2011;50:2083–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, et al. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol. 2009;44:872–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon–ribavirin combination therapy. Intervirology. 2005;48:372–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology. 2001;288:379–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differently regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA. 1998;95:15623–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Milella M, Antonelli G, Santantonio T, Currenti M, Monno N, Mariano N, et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver. 1993;13:146–50.PubMedGoogle Scholar
  24. 24.
    Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in chronic hepatitis C. J Hepatol. 1988;28:375–81.CrossRefGoogle Scholar
  25. 25.
    Scaqnolari C, Trombetti S, Solda A, Milella M, Gaeta GB, Angarano G, et al. Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α. Clin Microbiol Infect. 2012;18:1033–9.CrossRefGoogle Scholar
  26. 26.
    Matsuda F, Torii Y, Enomoto H, Kuga C, Aizawa N, Iwata Y, et al. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C. J Viral Hepat. 2012;19:694–703.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Tatsuo Kanda
    • 1
  • Shingo Nakamoto
    • 1
  • Makoto Arai
    • 1
  • Tatsuo Miyamura
    • 1
  • Shuang Wu
    • 1
  • Keiichi Fujiwara
    • 1
  • Osamu Yokosuka
    • 1
  1. 1.Department of Gastroenterology and NephrologyGraduate School of Medicine, Chiba UniversityChibaJapan

Personalised recommendations